TN2015000007A1 - 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments - Google Patents

3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments

Info

Publication number: TN2015000007A1
Authority: TN; Tunisia
Prior art keywords: production; medicaments; methods; pharmaceutical preparations; preparations containing
Prior art date: 2012-07-10

Application number

TNP2015000007A

Other languages

English (en)

Inventor

Ulrich Bothe

Matthias Busemann

Oliver Martin Fischer

Naomi Barak

Andrea Rotgeri

Tobias Marquardt

Christian Stegmann

Original Assignee

Bayer Pharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-07-10

Filing date

2015-01-07

Publication date

2016-06-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48748225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2015000007(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-01-07 Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG

2016-06-29 Publication of TN2015000007A1 publication Critical patent/TN2015000007A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pulmonology (AREA)
Gynecology & Obstetrics (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TNP2015000007A 2012-07-10 2015-01-07 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments TN2015000007A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102012211970		2012-07-10
PCT/EP2013/064257 WO2014009274A1 (fr)	2012-07-10	2013-07-05	Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments

Publications (1)

Publication Number	Publication Date
TN2015000007A1 true TN2015000007A1 (en)	2016-06-29

Family

ID=48748225

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2015000007A TN2015000007A1 (en)	2012-07-10	2015-01-07	3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments

Country Status (27)

Country	Link
US (1)	US9512169B2 (fr)
EP (1)	EP2872524B1 (fr)
JP (1)	JP6196302B2 (fr)
KR (1)	KR20150036319A (fr)
CN (1)	CN104428309B (fr)
AP (1)	AP2014008179A0 (fr)
AR (1)	AR092025A1 (fr)
AU (1)	AU2013289344A1 (fr)
BR (1)	BR112015000443A2 (fr)
CA (1)	CA2878485A1 (fr)
CL (1)	CL2015000039A1 (fr)
CO (1)	CO7160008A2 (fr)
CR (1)	CR20150007A (fr)
DO (1)	DOP2015000005A (fr)
EA (1)	EA201500112A1 (fr)
EC (1)	ECSP15000868A (fr)
ES (1)	ES2603258T3 (fr)
IL (1)	IL236581A0 (fr)
MA (1)	MA37742B1 (fr)
MX (1)	MX2015000347A (fr)
PE (1)	PE20150353A1 (fr)
PH (1)	PH12015500062A1 (fr)
TN (1)	TN2015000007A1 (fr)
TW (1)	TW201402596A (fr)
UY (1)	UY34899A (fr)
WO (1)	WO2014009274A1 (fr)
ZA (1)	ZA201500920B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN105008382B (zh) *	2013-02-21	2018-01-30	拜耳医药股份公司	用于抑制17β‑羟类固醇脱氢酶(AKR1 C3)的雌甾‑1,3,5(10),16‑四烯‑3‑羧酰胺
CN106687471B (zh) *	2014-09-11	2018-10-30	拜耳医药股份公司	3-氮或者硫取代的雌甾-1,3,5(10),16-四烯akr1c3抑制剂
US10167293B2 (en)	2016-05-26	2019-01-01	Bayer Pharma Aktiengesellschaft	[8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones
CZ307437B6 (cs)	2016-06-07	2018-08-22	Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i.	15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz
EP3269373A1 (fr)	2016-07-11	2018-01-17	Bayer Pharma Aktiengesellschaft	Formes posologiques orales à faible dosage d'un inhibiteur de akr1c3 pour le traitement des maladies
TW201825478A (zh)	2016-12-19	2018-07-16	德商拜耳製藥公司	［４－（苯基磺醯基）哌嗪－１－-基］（１ｈ－１，２，３－三唑－４-基）甲酮
CA3047191A1 (fr)	2016-12-19	2018-06-28	Bayer Pharma Aktiengesellschaft	[4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones
US20200085791A1 (en)	2016-12-19	2020-03-19	Bayer Pharma Aktiengesellschaft	[(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones
EP3421483A1 (fr)	2017-06-29	2019-01-02	Bayer Pharma Aktiengesellschaft	Nouveaux dérivés 17-beta-hétéroaryle des stéroïdes comme inhibiteurs de akr1c3
CN110693892A (zh) *	2018-07-09	2020-01-17	深圳艾欣达伟医药科技有限公司	化合物用于制备预防、治疗或改善疼痛的药物的用途
CN110272465A (zh) *	2019-07-15	2019-09-24	成都贝诺科成生物科技有限公司	阿比特龙衍生物、其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE186913T1 (de) *	1992-03-31	1999-12-15	Btg Int Ltd	17-substituierte steroide, verwendbar bei behandlung von krebs
US5604213A (en)	1992-03-31	1997-02-18	British Technology Group Limited	17-substituted steroids useful in cancer treatment
IL122740A (en)	1997-01-15	2003-09-17	Akzo Nobel Nv	16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
ES2200334T3 (es)	1997-04-07	2004-03-01	Wyeth	Estra-5(10),7-dieno con actividad estrogenica.
JP2002506077A (ja)	1998-03-11	2002-02-26	アンドルシェルシュ・インコーポレイテッド	タイプ５およびタイプ３１７β−ヒドロキシステロイドデヒドロゲナーゼのインヒビターおよびその使用法
ID28791A (id)	1998-08-07	2001-07-05	Endorech Inc	PENGHAMBATAN DEHIDROGENASE HIDROKSISTEROID 3α TIPE 3
EP1284272A4 (fr) *	2000-04-24	2003-09-10	Kyowa Hakko Kogyo Kk	Derives d'estra-1,3,5(10)-triene
US7498322B2 (en)	2004-03-12	2009-03-03	Entremed, Inc.	Antiangiogenic agents
EP1990335A4 (fr)	2006-03-02	2009-11-11	Astellas Pharma Inc	Inhibiteur de la 17 beta hsd de type 5
AU2007327653B2 (en)	2006-11-30	2013-04-18	Solvay Pharmaceuticals Gmbh	Substituted estratrien derivatives as 17beta HSD inhibitors
EP2097376A2 (fr)	2006-12-22	2009-09-09	F. Hoffmann-Roche AG	Dérivés de spiropipéridine
CA2694216A1 (fr)	2007-07-24	2009-01-29	Astellas Pharma Inc.	Derive de benzimidazole
DE102011083725A1 (de)	2011-09-29	2013-04-04	Bayer Pharma AG	Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln

2013
- 2013-07-05 ES ES13734744.9T patent/ES2603258T3/es active Active
- 2013-07-05 EP EP13734744.9A patent/EP2872524B1/fr active Active
- 2013-07-05 KR KR20157002707A patent/KR20150036319A/ko not_active Withdrawn
- 2013-07-05 PE PE2015000018A patent/PE20150353A1/es not_active Application Discontinuation
- 2013-07-05 AU AU2013289344A patent/AU2013289344A1/en not_active Abandoned
- 2013-07-05 JP JP2015520927A patent/JP6196302B2/ja not_active Expired - Fee Related
- 2013-07-05 EA EA201500112A patent/EA201500112A1/ru unknown
- 2013-07-05 US US14/414,386 patent/US9512169B2/en not_active Expired - Fee Related
- 2013-07-05 MX MX2015000347A patent/MX2015000347A/es unknown
- 2013-07-05 BR BR112015000443A patent/BR112015000443A2/pt not_active IP Right Cessation
- 2013-07-05 CN CN201380036684.4A patent/CN104428309B/zh not_active Expired - Fee Related
- 2013-07-05 CA CA2878485A patent/CA2878485A1/fr not_active Abandoned
- 2013-07-05 AP AP2014008179A patent/AP2014008179A0/xx unknown
- 2013-07-05 WO PCT/EP2013/064257 patent/WO2014009274A1/fr not_active Ceased
- 2013-07-10 TW TW102124795A patent/TW201402596A/zh unknown
- 2013-07-10 AR ARP130102438A patent/AR092025A1/es unknown
- 2013-07-10 UY UY0001034899A patent/UY34899A/es not_active Application Discontinuation
2015
- 2015-01-05 IL IL236581A patent/IL236581A0/en unknown
- 2015-01-07 TN TNP2015000007A patent/TN2015000007A1/fr unknown
- 2015-01-07 MA MA37742A patent/MA37742B1/fr unknown
- 2015-01-08 CL CL2015000039A patent/CL2015000039A1/es unknown
- 2015-01-09 CO CO15004249A patent/CO7160008A2/es unknown
- 2015-01-09 EC ECIEPI2015868A patent/ECSP15000868A/es unknown
- 2015-01-09 DO DO2015000005A patent/DOP2015000005A/es unknown
- 2015-01-09 PH PH12015500062A patent/PH12015500062A1/en unknown
- 2015-01-09 CR CR20150007A patent/CR20150007A/es unknown
- 2015-02-09 ZA ZA2015/00920A patent/ZA201500920B/en unknown

Also Published As

Publication number	Publication date
US9512169B2 (en)	2016-12-06
HK1205743A1 (en)	2015-12-24
ECSP15000868A (es)	2016-01-29
EA201500112A1 (ru)	2015-07-30
CO7160008A2 (es)	2015-01-15
PH12015500062A1 (en)	2015-03-02
JP2015522050A (ja)	2015-08-03
MA37742A1 (fr)	2016-05-31
CR20150007A (es)	2015-03-13
DOP2015000005A (es)	2015-02-15
US20150210734A1 (en)	2015-07-30
BR112015000443A2 (pt)	2017-06-27
MX2015000347A (es)	2015-04-14
CL2015000039A1 (es)	2015-03-27
AU2013289344A1 (en)	2015-02-05
EP2872524B1 (fr)	2016-08-24
IL236581A0 (en)	2015-02-26
UY34899A (es)	2014-02-28
CA2878485A1 (fr)	2014-01-16
CN104428309B (zh)	2016-09-14
ES2603258T3 (es)	2017-02-24
EP2872524A1 (fr)	2015-05-20
KR20150036319A (ko)	2015-04-07
WO2014009274A1 (fr)	2014-01-16
CN104428309A (zh)	2015-03-18
JP6196302B2 (ja)	2017-09-13
MA37742B1 (fr)	2016-12-30
PE20150353A1 (es)	2015-03-28
AR092025A1 (es)	2015-03-18
TW201402596A (zh)	2014-01-16
ZA201500920B (en)	2017-01-25
AP2014008179A0 (en)	2014-12-31

Publication	Publication Date	Title
TN2015000007A1 (en)	2016-06-29	3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
MY175804A (en)	2020-07-09	Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments
PH12015500274B1 (en)	2020-02-19	Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
GB201209613D0 (en)	2012-07-11	New compounds
PH12015500713A1 (en)	2015-05-18	Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
MY169159A (en)	2019-02-19	Piperidino-pyrimidine derivatives for the treatment of viral infections
MX349004B (es)	2017-07-06	Nuevos compuestos.
TN2015000278A1 (en)	2016-10-03	Autotaxin inhibitors
MY169987A (en)	2019-06-19	Selective pi3k delta inhibitors
MX366899B (es)	2019-07-30	Nuevos compuestos.
GB201118656D0 (en)	2011-12-07	New compounds
PH12015500724A1 (en)	2015-06-01	1, 2, 4-triazine derivatives for the treatment of viral infections
PH12015502564B1 (en)	2016-02-22	Pyridone derivatives for the treatment of viral infections and further diseases
IN2014DN09437A (fr)	2015-07-17